Waltham, Massachusetts – (The Hosting News) – January 23, 2008 – Web host and integrated data management solutions firm, Phase Forward Incorporated, will release its financial results for the quarter ending December of 2007, and hold a conference call with investors on Thursday, January 31, 2008.
Bob Weiler, President and Chief Executive Officer will host the investor conference call, including Rodger Weismann, Senior Vice President and Chief Financial Officer, to discuss its fourth quarter and full year 2007 financial results and its outlook for the first quarter and full year 2008. The call will be held at 5:00 p.m. (EST).
The investor conference call will be available via live webcast on Phase Forward’s web site under the tab Investors.To participate by telephone, the domestic dial-in number is 888-713-4217 and the international dial-in is 617-213-4869. The access code is 53879801. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection. The webcast will be available for replay until Friday, February 29, 2008 on the Investors page of Phase Forward’s website.
Phase Forward is a provider of web hosting and integrated data management solutions for clinical trials and drug safety. The company offers solutions for electronic data capture (InForm), clinical data management (Clintrial), clinical trials signal detection (CTSD), strategic pharmacovigilance (WebVDME) and Signal Management), adverse event reporting (Clintrace) and applied data standards (WebSDM). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 250 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug Administration, GlaxoSmithKline, Merck, U.K. Medicines and Healthcare Products Regulatory Agency, National Institutes of Health, Procter and Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Serono and Servier.
To learn more, please visit: www.phaseforward.com.